Full-Time

Head of Corporate Affairs & Patient Excellence

Confirmed live in the last 24 hours

Takeda

Takeda

10,001+ employees

Develops and commercializes biopharmaceuticals and vaccines

No salary listed

Senior, Expert

Mumbai, Maharashtra, India + 1 more

More locations: Noida, Uttar Pradesh, India

The job is based in two cities: Mumbai and Gurgaon, India.

Category
Human Resources
People & HR
Required Skills
Public Policy
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Takeda referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • Graduate/ Post Graduate in public policy.
  • Held progressive roles for last 15+ years in public affairs/market access and Corporate Communication /CSR with minimum 5 years in leadership in pharma/related industries;
  • Understanding of India’s health, policies, healthcare economic ecosystem, patient communities at large and their ways of working.
Responsibilities
  • Develop unified public policy and patient advocacy including access strategies focused on the value creation for patients, healthcare transformation, and sustainable access to company’s focused therapy portfolio and other strategic areas in India and Sri Lanka.
  • Proactively develop public affairs strategies and with patient first mindset drive public-private partnerships aligned with Takeda’s priorities at LOC level.
  • Incumbent will lead and manage policy, external relations across Government, Trade Associations, Bilateral and multilateral organisation, NGOs, multi-stakeholder consortium/alliances and other relevant organisations/stakeholders.
  • Relationships-building and maintenance with key decision makers/agencies at the National/State level to develop support for company’s positions and priorities.
  • Work with decision makers in Government bodies and other related stakeholders to help build patient centric solution country level.
  • Provide the insights on the Government upcoming and latest Policies & regulations and proactively suggest the changes anticipated so that organization adapts as per the Local requirements.
  • Build and implement strategic priorities for the LOC to improve healthcare outcomes through strategic and trustful partnerships with patient organisations delivering innovative patient centric solutions.
  • Build the robust access strategy for LOC to support patients journey by providing sustainable, equitable access to medicines.
  • Develop strategy to provide HTA- HEOR and value proposition solutions to accelerate access in country’s public & private healthcare ecosystem in rare and underserved disease conditions in alignment with Regional and Global guidelines with necessary localization in accordance with the legal and compliance framework.
  • Provides competitor and payer trends, insights & intelligence to internal functions.
  • Implement Public Affairs initiatives to augment access efforts in rare disease and underserved diseases therapies at country/cluster level.
  • Work with cross-functional teams to identify, scope and lead patient advocacy projects which strengthen Takeda’s Reputation and Trust with Society and the patient communities at large.
  • Works with patient organizations to empower them to increase their share of voice regarding rare and complex diseases and influence government policies inclusive of these diseases.
  • Lead Public Affairs strategies in close alignment with Market Access, Regulatory, Medical Affairs & Marketing to advance company’s business goals and strategic/business priorities.
  • Play an active role in shaping the Healthcare environment by advocacy and networking activities with National/State Health Systems, wide range of govt officials in Ministries and Departments such as PMO, DOP, NPPA, CDSCO, Health, Environment, Biotechnology, Finance, ICMR etc, external Policy Audiences and influencers to optimize the institutional environment in order to contribute to better access for patients and the company’s growth.
  • Facilitate and provide a platform to talk to government stakeholders and identify leverage points for providing/expanding market access of Organization's existing/expanding product portfolio.
  • Actively engage with various Industry Chambers (FICCI/CII/PHD), Associations (IPA/IDMA/FOPE/OPPI), Trade Bodies, Committees, in order to build strong networks with government and statutory officials and assist in policy decisions that support Industry and organization.
  • Promote discourse among state government officials by bringing together local/regional experts and patient groups involved in the Therapy/portfolio to reinforce messaging.
  • Work closely with Ministry of Health on various projects involving Public Private Partnerships (PPP) at center level to support the larger objectives of the organization.
  • Build and develop the relationships with Patient Organizations and work in collaboration with them, building alliances and coalitions united by a common mission to provide access to quality healthcare to all patients in the disease area/Therapy area.
  • Lead the engagement drives with the PAGs at National Level and continue to consult the State support teams (Institutional/Access) on State initiatives with Patient Organizations in case of long term engagement requirements.
  • Build and curate organization perception as a solution provider in Patient Organizations/PAGs view and support in Therapy access advancement objectives of the org.
  • Would be a point of contact with country PAG and coordinate with the PAG for the smooth management/closure of all their requests (Sponsorships/Grants/Donations) and also ensure that these are fully aligned as per the company ethics and compliance SOPs.
  • Build better SOPs around Patient Group Engagements ensuring Compliance to Organization’s Ethics & Compliance SOPs at every step.
  • Develops Pricing strategies including governance and guidelines for the existing and pipeline products (close launch products) through in-depth opportunity mapping, competitive intelligence, and product prioritization, while ensuring alignment with regional and global guidelines for LOC.
  • Lead Takeda India communication strategies for India business (including issue and crisis communication), the communications advisor for India Leadership Team; and to profile Takeda as a patient-centric bio-pharmaceutical company.
  • Lead the Company’s Corporate Social Responsibility (CSR) strategy and initiatives to maintain an excellent corporate reputation. He/she establishes, develops, and maintains the strategic link between businesses needs and communication activities in the country.
Desired Qualifications
  • Understanding of Public Health Policies and anticipate new/upcoming changes, especially in rare and underserved diseases, including vaccines.
  • PR orientation
  • Existing network among health authorities at central and state level
  • Cross-functional collaboration
  • Policymaker engagement
  • Advocacy at local/national level/PAG
  • Strategize, Execution & Detail orientation
  • Understanding of tender processes and influencing.
  • Health economic ecosystem in the country.
  • Innovative Patient Access Programs with pharmaceuticals.
  • High-impact communication/presentation Skills
  • Stakeholder management
  • Credible/authentic presence and leadership skills
  • Network within govt. machinery/establishments
  • Integrity, honesty, perseverance, fairness
  • People Manager, Team player and capability to foster an inclusive environment within the team and beyond.

Takeda Pharmaceutical Company Limited is a global biopharmaceutical firm that focuses on developing and delivering treatments and vaccines for patients. The company invests heavily in research and development to create new molecular entities (NMEs) and has a pipeline that includes 11 NMEs, with plans for up to 15 product launches by FY2024. Takeda's products are aimed at healthcare providers, hospitals, and patients around the world, and the company collaborates with about 41,000 suppliers to ensure the production and distribution of its medicines. Unlike many competitors, Takeda emphasizes patient-centric values, ensuring that the needs of patients guide its operations. Additionally, Takeda is committed to environmental sustainability, recognizing the connection between environmental health and human health. The company's goal is to provide life-changing treatments while also addressing environmental risks that could affect public health.

Company Size

10,001+

Company Stage

IPO

Headquarters

Tokyo, Japan

Founded

1781

Simplify Jobs

Simplify's Take

What believers are saying

  • Takeda's focus on personalized medicine can increase treatment efficacy and patient satisfaction.
  • Expansion in Southeast Asia offers opportunities for increased market presence and revenue growth.
  • Collaborations with tech companies can accelerate R&D processes and reduce costs.

What critics are saying

  • Data breach could lead to financial and reputational damage for Takeda.
  • Antitrust litigation with Meijer may result in financial penalties or business practice changes.
  • High financial commitments in partnerships could strain resources if outcomes are not achieved.

What makes Takeda unique

  • Takeda has a 240-year history in the biopharmaceutical industry.
  • The company emphasizes patient-centric values in its operations and R&D efforts.
  • Takeda's robust pipeline includes 11 NMEs with plans for 15 product launches by FY2024.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Wellness Program

Tuition Reimbursement

Company News

CyberNews
Apr 15th, 2025
Hackers want $75,000 for data allegedly stolen from Takeda

A new account on an illicit forum bearing the moniker "beltway" claims that in April 2025, it exported around two million rows of user information from Takeda.com.

MLex
Mar 4th, 2025
Meijer seeks quick appeal in US antitrust case against Takeda

( March 4, 2025, 17:06 GMT | Official Statement) - MLex Summary: Meijer asked a US federal judge for leave to immediately appeal an order that sent its antitrust case against Takeda Pharmaceuticals over the drug Amitiza to arbitration.

BioSpace
Mar 3rd, 2025
Takeda-Protagonist Drug for Incurable Cancer Reduces Need for Blood Withdrawals in Phase III Trial

Protagonist, which will receive a $25 million milestone from Takeda thanks to the positive results, plans to submit the findings to regulators.

Access Health
Mar 3rd, 2025
Strengthening Access to Medicines in Southeast Asia: Highlights from Southeast Asia Access to Medicine (SEA AtM) Summit

ACCESS Health International, in collaboration with AVPN, SingHealth Duke-NUS Global Health Institute, and Takeda, successfully co-hosted the first Southeast Asia Access to Medicine (SEA AtM) Summit in Bangkok.

Pharmaceutical Technology
Feb 25th, 2025
Takeda broadens its deal with BridGene for up to $770m

Bridgene and Takeda have inked a deal worth $770m to develop small molecules for immunology and neurology.